Literature DB >> 24636847

Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.

Shuai Li1, Fangyu Zhou2, Shengxiang Ren3, Caicun Zhou4.   

Abstract

Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced non-small cell lung cancer (NSCLC) patient with EGFR mutation. We report a case here that an advanced lung adenocarcinoma with L858R mutation responded well to pemetrexed rechallenge after acquired resistance of erlotinib.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acquired resistance; Chemotherapy; EGFR-TKI; NSCLC; Pemetrexed; Rechallenge

Mesh：

Substances：

Year:  2014        PMID： 24636847     DOI： 10.1016/j.lungcan.2014.02.010

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  5 in total

1.  Excellent platinum dependent response to chemotherapy after relapse under TKI treatment in NSCLC with sensitizing EGFR mutations and no detectable resistance mutations: three case studies.

Authors:  Diego Kauffmann-Guerrero; Zulfiya Syunyaeva; Kathrin Kahnert; Amanda Tufman
Journal:  AME Case Rep       Date:  2019-10-04

2.  Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes.

Authors:  Xiangli Jiang; Bo Yang; Jiuqin Lu; Zhongli Zhan; Kai Li; Xiubao Ren
Journal:  Tumour Biol       Date:  2014-10-10

3.  Successful pemetrexed-containing chemotherapy for epidermal growth factor receptor mutation-positive adenosquamous cell carcinoma of the lung: A case report.

Authors:  Hiroko Watanabe; Tomohiro Tamura; Katsunori Kagohashi; Mio Kawaguchi; Koichi Kurishima; Hiroaki Satoh
Journal:  Mol Clin Oncol       Date:  2016-01-29

4.  Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations.

Authors:  Ting Ding; Fei Zhou; Xiaoxia Chen; Shijia Zhang; Yinan Liu; Hui Sun; Shengxiang Ren; Xuefei Li; Chao Zhao; Heyong Wang; Caicun Zhou
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

5.  SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness.

Authors:  Leiming Xia; Fan Yang; Xiao Wu; Suzhi Li; Chen Kan; Hong Zheng; Siying Wang
Journal:  Cancer Cell Int       Date:  2021-07-03       Impact factor: 5.722
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.